The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Dry Eye
Interventions
BIOLOGICAL

Secukinumab 10 mg/kg

Secukinumab was prepared in a sterile water solution.

BIOLOGICAL

Canakinumab 10 mg/kg

Canakinumab was prepared in a sterile water solution.

BIOLOGICAL

Placebo

The placebo solution for infusion contained 5% glucose.

Trial Locations (1)

01810

Ora Inc, 300 Brickstone Square,, Andover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY